肝活检 肝脏良性病变 肝脏恶性病变的介入治疗
返回首页
  • [门静脉血栓] TIPS适应症:门静脉血栓 日期:2021-11-20 14:56:09 点击:99

    Non-tumoral PVT is the most common thrombotic event in patients with cirrhosis, with an annual incidence of up to 12%[127,128]. 非肿瘤性PVT是肝硬化患者中最常见的血栓性事件,每年的发病率高达12%的[127,128]。 Asymptomatic presentation is commo...

  • [概论] 概论 日期:2021-11-14 08:54:48 点击:99

    Hepatic cirrhosis is a chronic disease histologically characterized by the presence of regenerative nodules surrounded by diffuse fibrosis(21). 肝硬化是一种慢性疾病,其组织学特征是弥漫性再生结节周围的纤维化(21)。 It is the common final s...

  • [早期/优先TIPS] 优先TIPS 日期:2021-10-17 23:11:20 点击:99

    Acute variceal bleeding (AVB), which accounts for 70% of all upper gastrointestinal bleeding episodes in cirrhosis,[1] has been identified as a common cause of death in patients with cirrhosis, with a 6-week mortality around 20%. 急性静脉...

  • [临床表现] 非肝硬化门静脉高压:临床表现 日期:2021-09-18 13:36:07 点击:99

    When to Suspect PSVD? 何时怀疑PSVD? There are two clinical scenarios in whom PSVD can be suspected: patients with chronic and unexplained alteration of liver enzymes without portal hypertension and patients with unexplained clinically evi...

  • [概论] 非肝硬化门脉高压概论 日期:2021-09-17 10:29:36 点击:99

    The term non-cirrhotic portal hypertension (NCPH) refers to a heterogeneous group of liver disorders that primarily affect the liver vascular system and that are classified anatomically on the basis of site of resistance to blood flow, as...

  • [PSVD] PSVD 日期:2021-09-17 10:26:52 点击:99

    Porto sinusoidal vascular liver disease (PSVD) is a vascular liver disease characterized by portal hypertension in the absence of cirrhosis and other causes of liver disease[1]. 门窦性血管性肝病(PSVD)是一种以血管性肝病为特征的门静脉高压,...

  • [病理生理] 非肝硬化门静脉高压:病理生理机制 日期:2021-09-15 16:29:29 点击:99

    发病机制 到目前为止,INCPH 的具体病理生理机制尚不 明确。分二元理论和统一理论 二元理论: 认为,肝内血管闭塞所致 门静脉血流阻力增加和脾大继发门静脉血流增加是 导致 INCPH 患者门静脉高压的两个主要因素。肝 内血管闭塞的具体原因尚不清楚 统一理论:...

  • [流行病学] 非肝硬化门脉高压:流行病学 日期:2021-09-15 13:45:34 点击:99

    INCPH 在世界各地都有报道,它在西方较为罕 见,而在发展中国家,其发病率更高。性别比例在不同国家有所不同,在西方国家和印度多见于男 性,而在日本则多发于女性。发病年龄不定,在印度,其发病年龄约 25 ~ 35 岁,在日本,其发病年龄约 50 岁,而 在 西...

  • [SIRT 联合免疫治疗] 钇90+O药(免疫治疗) 日期:2021-09-12 18:11:44 点击:99

    肝癌是全世界范围内常见的消化系统恶性肿瘤,我国肝癌的发病率和死亡率在恶性肿瘤中分别排列第4位和第2位。肝癌具有早诊困难、进展迅速,预后较差等特征, 特别是对于中晚期肝癌患者的治疗选择非常有限。 一项2期临床试验评估了钇90微球疗法联合免疫药物Opdiv...

  • [TIPS:理想的支架直径] TIPS:理想的支架直径 日期:2021-09-10 15:02:45 点击:99

    Optimal stent diameter The 8-mm vs 10-mm debate: The availability of covered stents for TIPS has significantly reduced the incidence of stent dysfunction with attendant improvement in patient outcomes[206]. 最佳支架直径 8mm和10mm的争论:覆...

  • 首页
  • 上一页
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 下一页
  • 末页
  • 59589
推荐内容